Antimicrobial susceptibility testing for Escherichia coli strains to fluoroquinolones, in urinary tract infections

Iranian Journal of Public Health

Volumn 36, Issue 1, 2007, Pages 89-92

  Nakhjavani, F A ^a   Mirsalehian, A ^a   Hamidian, Mohammad ^a   Kazemi, B ^b   Mirafshar, M ^a   Jabalameli, F ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

E.coli; Fluoroquinolones; Iran; Resistance; Urinary tract infection; UTI

Indexed keywords

EID: 33947524271     PISSN: 22516085     EISSN: 22516093     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Kunin CM (1994). Urinary tract infections in females. Clin Infect Dis, (18):1-12.
2. Kriger JN, Kaiser DL, Wenzel RP (1983). Nosocomial urinary tract infections: Secular trends, Treatment and economics in a university hospital. J Urol, (130): 102-6.
3. Barnett BJ, Stephens DS (1997). Urinary tract infection an overview. Am J Med Sci, (4): 245-49.
4. Zakaria EA (2005). Increasing ciprofloxacin resistance among prevalent urinary tract bacterial isolates in Gaza Strip, Palestine. J Biom and Biotech, (3): 238-41.
5. Dimitriv TS, udo EE, Emara M, Awni F, Passadilla R (2004). Etiology and antibiotic susceptibility patterns of community-acquired urinary tract infections in a Kuwait Hospital. Med Princ Pract, (13): 334-39.
6. Sirot DL, Goldstein FW, Soussy CJ, Courtien AL (1992). Resistance to cefotaxime and seven other beta-lactams in members of the family Enterobacteriaceae: A 3-year survey in France. Antimicrob Agents Chemother, (36):1677-81.
7. Wayne P (2004). Performance Standards for Antimicrobial Susceptibility Testing. National Committee for Clinical Laboratory Standards. Eleventh Informational Supplement of NCCLSt, Document M100-S11.
8. Foxman B, Barlow R, Arcy H, Gillespie B, Sobel JD (2000). Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol, (10): 509-15.
9. Foxman B (2002). Epidemiology of urinary tract infections: incidence, morbidity, and economic costs, Am J Med, 113 (Suppl. 1A): 5S-13S.
10. Shao HF, Wang WP, Zhang XW, Li ZD (2003). Distribution and resistance trends of pathogens from urinary Tract infections and impact on management. Zhonghua Nan Ke Xue, 9(9): 690-96.
11. Iqbal J, Rahman M, Kabir MS, Rahman M (1997). Increasing ciprofloxacin resistance among prevalent urinary tract bacterial isolates in Bangladesh. Jpn J Med Sci Boil, 50(6): 241-50.
12. Karl D, Muhammad M. (2003). Fluoroquinolones: Action and Resistance. Current Topics in Medicinal Chemistry, (3): 249-82.
13. Weber G, Reisenberg K, Schlaeffer F, Peled N, Borer A, Yagupsky P (1997). Changing trends in frequencyand antimicrobial resistance of urinarypathogens in outpatient clinics and a hospital in southern Israel, 1991-1995. Eur J Clin Microbiol Infect Dis, (16): 834-38.
14. Ferhat C, Cibali ZA (2004). Increasing incidence of quinolone-resistant E. coli from urinary cultures in Ankara-Pursaklar region Letter. Antimicrobial Agents Chemother, (23): 416-17.